lobbying_activities: 3427758

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
3427758	4ad1e195-6303-428c-9f14-47570c6b11d3	Q3	ELITE STRATEGIC SERVICES	401108852	CONSERVATIVES FOR PROPERTY RIGHTS	2025	third_quarter	LBR	H.R. 384 (One Agency Act) S. 1040 (Drug Competition Enhancement Act) S. 1096 (Preserve Access to Affordable Generics and Biosimilars Act) Seeking ways to lower prescription drug prices by promoting competition without expropriating patent rights	Federal Trade Commission (FTC),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),SENATE	23000		0	0	2025-10-06T09:48:51-04:00